For several decades, the gene editing sector has been marked by rapid advancements and experimental treatments. Researchers began exploring the possibilities of modifying genes to treat various genetic diseases. However, due to unstandardized processes, these early iterations of gene editing led to inconsistent results and safety concerns. Today's pioneers in the space are still grappling with these issues. Companies and their researchers are navigating uncharted territory with minimal oversight. According to Bundy, this is where CRISPR QC is working to install an essential framework. Gene editing is the process of modifying an organism's DNA. CRISPR QC's analytics platform, powered by a proprietary CRISPR-Chip and deep machine learning, offers a newfound precision and real-time insight into the gene editing process. The technology measures how any formulation of CRISPR will operate on any target DNA, mimicking aspects of the cells that might be experienced in the editing process.